Jumpstart Pays Faster than Discovery: The Moral of the TransForm/J&J Acquisition
This article was originally published in Start Up
Executive Summary
With its acquisition of TransForm, J&J has cemented its position as the Big Pharma most interested in the power of jumpstart strategies to create new drugs. The new deal is dwarfed by J&J's 2001 acquisition of Alza, but philosophically the two deals are very much the same--platform technologies that quickly generate relatively low-risk product opportunities for J&J.